Riskpilot← Back to searchSign inGet full accessNXbio Development AB
ABActiveOrg 5565121794Storjordenvägen 2Manufacture of pharmaceutical preparations · NACE 2120Est. 19952 employees
Revenue 2024
SEK 0
EBITDA margin
—
+44% vs 2023
Equity ratio
36.7%
Financial strength
Net profit 2024
SEK -11M
+76% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -79K | +44% |
| Net profit | SEK -11M | +76% |
| Total assets | SEK 191,8M | +49% |
| Equity | SEK 70,4M | -13% |
| Employees | 2 | — |
Legal name
NXbio Development AB
Org number
5565121794
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
11 april 1995
Share capital
SEK 3 775 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas i förening av ledamöterna Firman tecknas två i förening av ledamöterna suppleanten
Company purpose
Bolaget ska direkt eller indirekt bedriva utveckling och tillverkning av läkemedelsprodukter och därmed förenlig verksamhet.
Address
Storjordenvägen 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2011 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29 874 | — | — | — | 5 230 | 1 102 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −7 999 | 5 186 | 5 198 | 5 182 | 5 170 | 1 080 | −38 | −44 | −166 | −142 | −79 |
| Depreciation & amort. | −4 800 | −5 230 | −5 230 | −5 230 | −5 221 | −1 102 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −12 799 | −44 | −32 | −48 | −51 | −22 | −38 | −44 | −166 | −142 | −79 |
| Net financials | −1 206 | −20 414 | −36 778 | −26 862 | −38 192 | −18 853 | −42 263 | −29 156 | −19 378 | −45 713 | −10 891 |
| Profit before tax | −14 005 | −19 700 | −36 810 | −26 910 | −38 244 | −18 875 | −42 301 | −29 199 | −19 543 | −45 517 | −10 969 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −14 005 | −19 700 | −36 810 | −26 910 | −38 244 | −18 875 | −42 301 | −29 199 | −19 543 | −45 517 | −10 969 |
| Item | 2011 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 51 616 | 22 311 | 27 234 | 44 155 | 41 265 | 57 692 | 117 855 | 165 589 | 203 258 | 128 923 | 191 803 |
| Equity | 9 656 | 4 590 | 4 079 | 3 779 | 2 336 | 3 810 | 3 409 | 146 405 | 126 862 | 81 345 | 70 375 |
| Long-term debt | 19 638 | 17 474 | 22 352 | 40 128 | 37 320 | 51 973 | 114 386 | 19 147 | 76 335 | 47 449 | 121 340 |
| Short-term debt | 22 321 | 247 | 803 | 248 | 1 610 | 1 909 | 60 | 38 | 61 | 129 | 88 |
| Total debt | 41 959 | 17 721 | 23 155 | 40 376 | 38 930 | 53 882 | 114 446 | 19 185 | 76 396 | 47 578 | 121 428 |
EBITDA margin
-7900000.0%
This company
15.8%
Market median
-50000100% vs market
20112024
Equity ratio
36.7%
This company
38.2%
Market median
+4% vs market
20112024
Return on equity
-15.6%
This company
18.4%
Market median
-185% vs market
20112024
Net profit margin
-1096900000.0%
This company
8.1%
Market median
-13541975409% vs market
20112024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20112024
Debt / equity
1.73×
This company
0.62×
Market median
-179% vs market
20112024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
- Annual report 2011Filed via Bolagsverket / SCB · Period 2010-05-01 – 2011-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB External Signatory | External Signatory | 2020 | — | — |
LC Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
RJ Chief Auditor | Chief Auditor | 2020 | — | — |
PA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AC Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NorthX Biologics Holding AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Flerie Invest AB
NXbio Development AB Board members of NXbio Development AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Bengt Eldered | External Signatory | 0 companies |
| Lars Christer Fahlander | Chief Executive Officer | 0 companies |
| Robert Jan Hasslund | Chief Auditor | 0 companies |
| Peter Alistair Coleman | Chief Executive Officer | 0 companies |
| Ann Charlott Bouvin | Chief Auditor | 0 companies |
| Wilhelmus, Johannes Antonius Maria Frieling | Chairman | 0 companies |
| Adriana Jannetje Hoogstraate | Board of Directors | 0 companies |
| Ted Ingemar Jakob Fjällman | Deputy Board Member | 0 companies |
| Maria Ingrid Rynell | Chairman | 0 companies |
| Sheena Jacqueline Pumford | Board of Directors | 0 companies |
| Jon Galli | Board of Directors | 0 companies |
| Ida Helena Christina Strigård | Board of Directors | 0 companies |
| James Kelly Ganjei | Chairman | 0 companies |
| Lars Peter Boman | Deputy Board Member | 0 companies |
| Sara Eva-Karin Sällstedt Gidlund | Deputy Board Member | 0 companies |